3D-QSAR and molecular docking analysis of biphenyl amide derivatives as p38α mitogen-activated protein kinase inhibitors

Molecular Diversity

Volumn 16, Issue 2, 2012, Pages 377-388

  Ambure, Pravin Sundarao ^a   Gangwal, Rahul Prakashchand ^a   Sangamwar, Abhay T ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Biphenyl amide; CoMFA; CoMSIA; Glide; LeapFrog; Molecular docking; P38 MAP kinase

Indexed keywords

AMIDE; MITOGEN ACTIVATED PROTEIN KINASE 14;

ARTICLE; BINDING AFFINITY; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG BINDING; DRUG DESIGN; DRUG STRUCTURE; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR DOCKING; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STATIC ELECTRICITY; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

AMIDES; BINDING SITES; BIPHENYL COMPOUNDS; ENZYME INHIBITORS; MITOGEN-ACTIVATED PROTEIN KINASE 14; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84864660805     PISSN: 13811991     EISSN: 1573501X     Source Type: Journal    
DOI: 10.1007/s11030-011-9353-y     Document Type: Article

References (27)

1. Foster ML, Halley F, Souness JE (2000) Potential of p38 inhibitors in the treatment of rheumatoid arthritis. Drug News Perspect 13:488-497 (Pubitemid 32063588)
2. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, Woody KL De (1999) Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117:761-769. doi:10.1016/S0016- 5085 (99) 70332-X (Pubitemid 29468216)
3. Badger AM, Bradbeer JN, Votta B, Lee JC, Adams JL, Griswold DE (1996) Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 279:1453-1461 (Pubitemid 27166795)
4. Feldmann M, Brennan FM, Maini RN (1996) Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14:397-440. doi:10. 1146/annurev. immunol.14.1.397 (Pubitemid 26130190)
5. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Keys JR (1994) A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372:739-746. doi:10.1038/372739a0
6. Jiang Y, Chen C, Li Z, Guo W, Gegner JA, Lin S, Han J (1996) Characterization of the structure and function of a new mitogen-activated protein kinase (p38α). J Biol Chem 271:17920-17926. doi:10.1074/jbc.271. 30.17920 (Pubitemid 26250772)
7. * 1. Biochem Biophys Res Commun 235:533-538. doi:10.1006/bbrc.1997.6849 (Pubitemid 27326515)
8. Jiang Y, Gram H, Zhao M, New L, Gu J, Feng L, Di Padova F, Ulevitch RJ, Han J (1997) Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinases, p38δ. J Biol Chem 272:30122. doi:10.1074/jbc.272. 48.30122
9. Newton R, Holden N (2003) Inhibitors of p38 mitogen-activated protein kinase: potential as anti-inflammatory agents in asthma. Biodrugs 17:113-129 (Pubitemid 36433993)
10. Brennan FM, Feldmann M (1996) Cytokines in autoimmunity. Curr Opin Immunol 8:872-877. doi:10.1016/S0952-7915 (96) 80018-5 (Pubitemid 27007655)
11. Camussi G, Lupia E (1998) The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis. Drugs 55:613-620 (Pubitemid 28203770)
12. Adams JL, Badger AM, Kumar S, Lee JC (2001) 1 p38 MAP kinase: molecular target for the inhibition of pro-inflammatory cytokines. Prog Med Chem 38:1-60. doi:10.1016/S0079-6468 (08) 70091-2
13. Gallagher TF, Seibel GL, Kassis S, Laydon JT, Blumenthal MJ, Lee JC, Lee D, Boehm JC, Fier-Thompson SM, Abt JW (1997) Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase. Bioorg Med Chem 5:49-64. doi:10. 1016/S0968-0896 (96) 00212-X (Pubitemid 27065349)
14. Liverton NJ, Butcher JW, Claiborne CF, Claremon DA, Libby BE, Nguyen KT, Pitzenberger SM, Selnick HG, Smith GR, Tebben A (1999) Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogenactivated protein kinase. JMed Chem 42:2180-2190. doi:10.1021/jm9805236 (Pubitemid 29284237)
15. Angell RM, Angell TD, Bamborough P, Brown D, Brown M, Buckton JB, Cockerill SG, Edwards CD, Jones KL, Longstaff T (2008) Biphenyl amide p38 kinase inhibitors 2: optimisation and SAR. Bioorg Med Chem Lett 18:324-328. doi:10.1016/j.bmcl. 2007.10.043
16. Angell R, Aston NM, Bamborough P, Buckton JB, Cockerill S, deboeck SJ, Edwards CD, Holmes DS, Jones KL, Laine DI (2008) Biphenyl amide p38 kinase inhibitors 3: improvement of cellular and in vivo activity. Bioorg Med Chem Lett 18:4428-4432. doi:10.1016/j.bmcl.2008.06.048
17. Angell RM, Bamborough P, Cleasby A, Cockerill SG, Jones KL, Mooney CJ, Somers DO, Walker AL (2008) Biphenyl amide p38 kinase inhibitors 1: discovery and binding mode. Bioorg Med Chem Lett 18:318-323. doi:10.1016/j.bmcl.2007.10. 076
18. Angell RM, Angell TD, Bamborough P, Bamford MJ, Chung C, Cockerill SG, Flack SS, Jones KL, Laine DI, Longstaff T (2008) Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes. Bioorg Med Chem Lett 18:4433-4437. doi:10.1016/j.bmcl.2008.06.028
19. SYBYL, version 7.1; (2006) Tripos associates. St. Louis, MO, USA
20. Powell MJD (1977) Restart procedures for the conjugate gradient method. Math Program 12:241-254. doi:10.1007/BF01593790
21. Gasteiger J, Marsili M (1980) Iterative partial equalization of orbital electronegativity-a rapid access to atomic charges. Tetrahedron 36:3219-3228. doi:10.1016/0040-4020 (80) 80168-2
22. Nandi S, Bagchi MC (2010) 3D-QSAR and molecular docking studies of 4-anilinoquinazoline derivatives: a rational approach to anticancer drug design. Mol Divers 14:27-38. doi:10.1007/s11030-009-9137-9
23. Gupta P, Garg P, Roy N (2011) Comparative docking and CoMFA analysis of curcumine derivatives as HIV-1 integrase inhibitors. Mol Divers 15:1-18. doi:10.1007/s11030-011-9304-7
24. Melagraki G, Afantitis A, Sarimveis H, Koutentis PA, Markopoulos J, Igglessi-Markopoulou O (2007) A novel QSPR model for predicting Î, (lower critical solution temperature) in polymer solutions using molecular descriptors. J Mol Model 13:55-64. doi:10. 1007/s00894-006-0125-z (Pubitemid 44823953)
25. Glide, Version 5.5, (2009) Schrödinger, LLC, New York
26. SYBYL Ligand-Based Design Manual version 7.1, Tripos Inc., St. Louis
27. Goodford PJ (1985) A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem 28:849-857. doi:10.1021/jm00145a002 (Pubitemid 15012490)